Crystallographic insights into the structure-activity relationships of diazaborine enoyl-ACP reductase inhibitors

Enoyl-ACP reductase, the last Enzyme of the fatty-acid biosynthetic pathway, is the molecular target for several successful Antibiotics such as the tuberculosis therapeutic isoniazid. It is currently under investigation as a narrow-spectrum Antibiotic target for the treatment of several types of Bacterial infections. The diazaborine family is a group of boron heterocycle-based synthetic Antibacterial inhibitors known to target enoyl-ACP reductase. Development of this class of molecules has thus far focused solely on the sulfonyl-containing versions. Here, the requirement for the sulfonyl group in the diazaborine scaffold was investigated by examining several recently characterized enoyl-ACP reductase inhibitors that lack the sulfonyl group and exhibit additional variability in substitutions, size and flexibility. Biochemical studies are reported showing the inhibition of Escherichia coli enoyl-ACP reductase by four diazaborines, and the crystal structures of two of the inhibitors bound to E. coli enoyl-ACP reductase solved to 2.07 and 2.11 Å resolution are reported. The results show that the sulfonyl group can be replaced with an amide or thioamide without disruption of the mode of inhibition of the molecule.

Escherichia coli; NAD; antibiotics; binding sites; boron heterocycle; crystallography; enoyl-ACP reductase; enzyme inhibitors.